北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于上海建发致新医疗科技集团股份有限公司 2025 年第二次临时股东大会的 法律意见书 国枫律股字[2025]A0540 号 致：上海建发致新医疗科技集团股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2025 年第二次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律 业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《上海建发致新医疗 科技集团股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集 与召开程序、召集人资格、出席会议人员资格、 ...

证券代码：301584 证券简称：建发致新 公告编号：2025-013 上海建发致新医疗科技集团股份有限公司 2025年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会不存在否决议案的情形。 3.会议地点：上海市杨浦区秦皇岛路32号上海建发国际大厦9楼1号会议室 4.召开方式：现场表决与网络投票相结合。 5.现场会议主持人：董事长余峰先生 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.召集人：公司董事会 2.会议时间： （1）现场会议时间：2025年11月12日14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025年11月12日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为2025年11月12日9:15至15:00的任意时间。 6. 本次股东大会的召集、召开程序及表决方式符合《中华人民共和国公司法》 等法律、法规、规范性文件和《公司章程》的规定。 ...

Market Overview - As of November 12, the Shanghai Composite Index closed at 4000.14 points, down 2.62 points, a decrease of 0.07% [1] - The Shenzhen Component Index closed at 13240.62 points, down 48.39 points, a decrease of 0.36% [1] - The ChiNext Index closed at 3122.03 points, down 12.29 points, a decrease of 0.39% [1] High Turnover Stocks - 84 A-shares had a turnover rate exceeding 20% on this day, with Jianfa Zhixin reaching over 50% [1] - Jianfa Zhixin (stock code: 301584) had a closing price of 36.48 yuan, a turnover rate of 57.61%, and an increase of 14.64% [1] - Te Yi Pharmaceutical (stock code: 002728) closed at 13.41 yuan, with a turnover rate of 44.81% and an increase of 5.09% [1] - Zhongneng Electric (stock code: 300062) closed at 10.74 yuan, with a turnover rate of 43.83% and an increase of 1.99% [1] - Other notable stocks with high turnover rates include: - Fangzheng Electric (stock code: 002196) with a turnover rate of 40.77% and an increase of 5.88% [1] - Danna Biology (stock code: 920009) with a turnover rate of 39.96% and an increase of 9.99% [1] Additional High Turnover Stocks - Other stocks with significant turnover rates include: - Yihua Chemical (stock code: 301518) with a turnover rate of 31.04% and a decrease of 3.90% [2] - Aipeng Medical (stock code: 300753) with a turnover rate of 23.39% and an increase of 8.21% [3] - Guoyuan Technology (stock code: 688472) with a turnover rate of 20.12% and a decrease of 14.33% [3]

（原标题：建发致新11月12日龙虎榜数据） 建发致新今日上涨14.64%，全天换手率57.61%，成交额10.36亿元，振幅19.62%。龙虎榜数据显示，机构净买入8175.87万元，营业部席位合计净 买入526.82万元。 深交所公开信息显示，当日该股因日换手率达57.61%上榜，机构专用席位净买入8175.87万元。 证券时报•数据宝统计显示，上榜的前五大买卖营业部合计成交1.95亿元，其中，买入成交额为1.41亿元，卖出成交额为5399.61万元，合计净买入 8702.69万元。 具体来看，今日上榜的营业部中，共有4家机构专用席位现身，即买一、买二、买三、买四，合计买入金额1.01亿元，卖出金额1894.41万元，合计 净买入8175.87万元。 近半年该股累计上榜龙虎榜12次，上榜次日股价平均跌0.90%，上榜后5日平均跌0.16%。 相关ETF 数字经济ETF (产品代码: 560800) ★ 跟踪：中证数字经济主题指数 近五日涨跌：-1.57% 市盈率: 67.94倍 资金流向方面，今日该股主力资金净流入6571.41万元，其中，特大单净流入4732.11万元，大单资金净流入1839.30万元。近 ...

Core Viewpoint - The pharmaceutical commercial sector experienced a significant surge, with the sector index reaching a new high for the year [1]. Group 1: Market Performance - Individual stocks such as YaoYigou saw a rapid increase, hitting a 20% limit up within approximately 4 minutes of opening [3]. - HeFu China achieved a limit up after a strong opening, marking 11 limit ups in the last 12 trading days [3]. - RenMin TongTai opened with a limit up, achieving three consecutive limit ups [3]. Group 2: Stock Details - YaoYigou: +19.99%, previous amount 3.75 billion, current market cap 33.59 billion, current price 35.14 [4]. - JianFa ZhiXin: +14.86%, previous amount 9.66 billion, current market cap 154.01 billion, current price 36.55 [4]. - RenMin JianTan: +10.04%, previous amount 59.297 million, current market cap 72.49 billion, current price 12.50 [4]. - HeLiang China: +10.02%, previous amount 12.16 billion, current market cap 79.97 billion, current price 20.09 [4]. - DaShenLin: +4.67%, previous amount 3.23 billion, current market cap 222.1 billion, current price 19.50 [4]. - YiFeng Pharmacy: +2.80%, previous amount 3.71 billion, current market cap 303.0 billion, current price 24.99 [4].

Core Viewpoint - The pharmaceutical commercial sector experienced a significant surge, with the sector index reaching a new high for the year [1]. Group 1: Market Performance - Individual stocks such as YaoYigou saw a rapid increase, hitting a 20% limit up within just 4 minutes of opening [3]. - HeFu China opened high and quickly reached a limit up, achieving 11 limit up days in the last 12 trading days [3]. - RenMin TongTai opened with a limit up and secured three consecutive limit up days [3]. Group 2: Stock Details - YaoYigou (300937) increased by 19.99%, with a total amount of 3.75 billion and a market cap of 33.59 billion, currently priced at 35.11 [4]. - JianFa ZhiXin (301584) rose by 14.86%, with a total amount of 9.66 billion and a market cap of 154 billion, currently priced at 36.55 [4]. - RenMin TongTai (600829) increased by 10.04%, with a total amount of 59.297 million and a market cap of 72.49 billion, currently priced at 12.50 [4]. - HeFu China (603122) rose by 10.02%, with a total amount of 12.16 billion and a market cap of 79.97 billion, currently priced at 20.09 [4]. - Other stocks like DaCanLin (603233) and YingTe Group (000411) also showed positive performance, with increases of 4.67% and 2.71% respectively [4].

Group 1 - The core viewpoint of the article highlights that Jianfa Zhixin (301584) has been operating in the SPD business for many years, with a significant focus on SPD management services for tertiary public hospitals [1] - The gross profit margin for the company's SPD management services is projected to be in the range of 30%-40% from 2022 to 2024 [1]

Core Insights - The pharmaceutical commercial sector experienced a decline of 0.52% on November 6, with Renmin Tongtai leading the drop [1] - The Shanghai Composite Index closed at 4007.76, up 0.97%, while the Shenzhen Component Index closed at 13452.42, up 1.73% [1] Stock Performance - The top-performing stock was HeFu China (603122), which closed at 14.34, up 9.97% with a trading volume of 1.2541 million shares and a transaction value of 1.757 billion [1] - Other notable gainers included Yinghe Shiyao (002788) at 9.33, up 5.19%, and Yingche Dong (002462) at 14.68, up 1.45% [1] - Conversely, Renmin Tongtai (600829) saw a significant drop of 9.98%, closing at 65.6 with a trading volume of 521,700 shares and a transaction value of 500 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 467 million from institutional investors, while retail investors saw a net inflow of 408 million [2] - The overall capital flow indicates that while institutional investors withdrew funds, retail investors were actively buying into the sector [2] Individual Stock Capital Flow - Notable net inflows from retail investors were observed in stocks like Yifeng Pharmacy (603939) with a retail net inflow of 412.67 million, while institutional investors had a net inflow of 287.47 million in Nanjing Pharmaceutical (600713) [3] - Conversely, stocks like Luyuan Pharmaceutical (002788) and Jia Shitang (002462) experienced net outflows from both institutional and retail investors [3]

Core Viewpoint - The stock of Jianfa Zhixin has experienced fluctuations, with a recent decline of 2.00% and a year-to-date drop of 5.06%, despite a notable increase in revenue and profit for the year [1][2]. Group 1: Stock Performance - As of November 5, Jianfa Zhixin's stock price is 34.71 CNY per share, with a trading volume of 1.29 billion CNY and a turnover rate of 7.33%, resulting in a total market capitalization of 14.623 billion CNY [1]. - The stock has seen a net inflow of 1.6118 million CNY from main funds, with significant buying and selling activity in large orders [1]. - The stock has appeared on the "Dragon and Tiger List" 11 times this year, with the most recent appearance on November 4, showing a net buy of -10.334 million CNY [1]. Group 2: Company Overview - Jianfa Zhixin Medical Technology Group Co., Ltd. was established on August 30, 2010, and is located in Yangpu District, Shanghai [2]. - The company specializes in direct sales and distribution of medical devices, providing centralized operation services for medical consumables to hospitals [2]. - The revenue composition includes: vascular intervention (55.61%), surgical instruments (21.46%), in vitro diagnostic reagents (13.05%), medical equipment (6.24%), and other medical devices (2.79%) [2]. Group 3: Financial Performance - For the period from January to September 2025, Jianfa Zhixin achieved a revenue of 14.861 billion CNY, representing a year-on-year growth of 10.18%, and a net profit attributable to shareholders of 230 million CNY, with a year-on-year increase of 45.01% [2]. - As of September 30, the number of shareholders has increased by 151.60% to 38,000, while the average circulating shares per person decreased by 60.25% to 1,327 shares [2].

Core Viewpoint - The stock of Jianfa Zhixin increased by 5.20% today, with a turnover rate of 36.94% and a trading volume of 646 million yuan, indicating significant market activity and interest in the stock [2]. Trading Activity - The stock was listed on the Dragon and Tiger list due to its turnover rate reaching 36.94%, with institutional investors net selling 12.96 million yuan [2]. - The top five trading departments on the list had a total transaction amount of 144 million yuan, with buying transactions amounting to 66.81 million yuan and selling transactions amounting to 77.14 million yuan, resulting in a net sell of 10.33 million yuan [2]. - Among the trading departments, four institutional specialized seats were involved, with total buying amounting to 52.58 million yuan and selling amounting to 65.54 million yuan, leading to a net sell of 12.96 million yuan [2]. Fund Flow - The stock experienced a net inflow of 22.84 million yuan from main funds today, with large orders contributing a net inflow of 15.10 million yuan and big orders contributing a net inflow of 7.73 million yuan [2]. - Over the past five days, the main funds have seen a net outflow of 22.84 million yuan [2]. Historical Performance - In the past six months, the stock has appeared on the Dragon and Tiger list 11 times, with an average price drop of 0.53% the day after being listed and an average increase of 2.93% over the following five days [2].